(Q37697797)

22 August 2017

1 reference

title

Cyclin-dependent kinase inhibitors: a survey of recent patent literature (English)

1 reference

22 August 2017

1

Hervé Galons

0 references

Laurent Meijer

series ordinal

3

object named as

Laurent Meijer

1 reference

22 August 2017

Hervé Galons

1

1 reference

22 August 2017

Nassima Oumata

series ordinal

2

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

Expert Opinion on Therapeutic Patents

22 August 2017

published in

1 reference

22 August 2017

volume

20

1 reference

22 August 2017

issue

3

1 reference

22 August 2017

page(s)

377-404

1 reference

The protein kinase complement of the human genome

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

Protein kinase resource: an integrated environment for phosphorylation research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

Multiple levels of cyclin specificity in cell-cycle control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

Cell-cycle control and cortical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

Pharmacological inhibitors of cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

CDK/GSK-3 inhibitors as therapeutic agents for parenchymal renal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

Advances on cyclin-dependent kinases (CDKs) as novel targets for antiviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

Apoptosis is essential for neutrophil functional shutdown and determines tissue damage in experimental pneumococcal meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

Cyclin-dependent kinase 5 activator p35 over-expression and amyloid beta synergism increase apoptosis in cultured neuronal cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

The functional role of an interleukin 6-inducible CDK9.STAT3 complex in human gamma-fibrinogen gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

Inhibitors of cyclin dependent kinases: useful targets for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

Flavopiridol in the treatment of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

CDK inhibitors in cancer therapy: what is next?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator, in undifferentiated nasopharyngeal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

CDK2/cyclinA inhibitors: targeting the cyclinA recruitment site with small molecules derived from peptide leads

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

Meriolins, a new class of cell death inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

The regulation of protein phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

Structure-guided discovery of cyclin-dependent kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

Identifying tumor cell growth inhibitors by combinatorial chemistry and zebrafish assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

The rise of fragment-based drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

High-throughput kinase profiling as a platform for drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

Roscovitine targets, protein kinases and pyridoxal kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

Off-target decoding of a multitarget kinase inhibitor by chemical proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

Cell cycle, CDKs and cancer: a changing paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

You never know: Cdk inhibitors as anti-cancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

State-dependent block of HERG potassium channels by R-roscovitine: implications for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

Roscovitine is an effective inducer of apoptosis of Ewing's sarcoma family tumor cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

A Cdk5 inhibitor enhances the induction of insulin secretion by exendin-4 both in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903524284

10.1517/13543770903524284

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference